Aktis Oncology to Present at Upcoming March Investor Conferences
Rhea-AI Summary
Aktis Oncology (NASDAQ:AKTS) announced that President and CEO Matthew Roden, Ph.D., will present at two investor conferences in March 2026: TD Cowen on March 3 and Leerink Partners on March 9.
Live webcasts will be available via the company's Investors site and archived replays will remain for about 90 days after each conference.
Positive
- None.
Negative
- None.
News Market Reaction – AKTS
In the Feb 25 session, AKTS declined 2.50%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 13 | IPO closing | Positive | -1.8% | Upsized IPO closing with full underwriters’ option at $18.00 per share. |
| Jan 09 | IPO accolades | Positive | +60115.1% | Backer congratulates Aktis on IPO, highlighting funding, pipeline and Lilly deal. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Early post-IPO trading shows one positive and one negative reaction to IPO-related news, indicating mixed follow-through around offerings and listing milestones.
Since early January 2026, Aktis Oncology has focused on its transition to the public markets. The company completed an upsized IPO at $18.00 per share, including full exercise of the underwriters’ option, and began trading on the Nasdaq Global Select Market. A subsequent congratulatory release highlighted IPO proceeds and pipeline assets. Today’s conference announcement fits a typical pattern of post-IPO investor outreach following these capital markets milestones.
Key Terms
radiopharmaceuticals medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the following investor conferences in March 2026.
TD Cowen 46th Annual Health Care Conference
Date & Time: Tuesday, March 3, 2026, at 1:10 p.m. ET
Location: Boston, MA
Leerink Partners Global Healthcare Conference
Date & Time: Monday, March 9, 2026, at 1:40 p.m. ET
Location: Miami, FL
A live webcast of the presentations may be accessed via the Investors section of the Aktis website at investors.aktisoncology.com. An archived replay of the event will be available on the website for approximately 90 days following the conference.
About Aktis’ Radioconjugate Platform
Aktis has developed a proprietary, isotope-agnostic miniprotein radioconjugate platform to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors. Aktis’ therapeutic miniprotein radioconjugates are designed to maximize anti-cancer activity through high penetration, internalization and retention in cancer cells, while quickly clearing from normal organs and tissues. The Aktis platform further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Leveraging this platform, Aktis is advancing a pipeline of next-generation targeted radiopharmaceuticals to address the unmet needs of patients across a broad spectrum of solid tumors.
About Aktis Oncology
Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis’ most-advanced program, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer. Aktis’ second pipeline program, AKY-2519, is a miniprotein radioconjugate targeting B7-H3 expressing tumors, including prostate, lung and other solid tumors. Aktis has a strategic collaboration with Eli Lilly and Company to leverage its miniprotein platform to develop novel radioconjugates outside of Aktis’ proprietary pipeline.
Media Contact:
Melone Communications, LLC
Liz Melone
617-256-6622
liz@melonecomm.com
Investor Contact:
Precision AQ
Alex Lobo
212-698-8802
alex.lobo@precisionaq.com
